PubMed
GHRP-2: a GH secretagogue for clinical use
Bowers CY. J Pediatr Endocrinol Metab. 1997
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 60% · Mixed 32% · Unfavorable overall 8%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 25–600 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 29 days · Based on 272 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 66% · Mixed 26% · Unfavorable overall 8%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 10–600 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 61% said they felt similar to their last entry, 28% more positive, and 16% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 23 days · Based on 531 repeat reporters
Published sources linked on the GHRP-2 and Sermorelin wiki pages.
PubMed
Bowers CY. J Pediatr Endocrinol Metab. 1997
PubMed
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
FDA Drug Label
Serono. FDA Drug Label. 1997
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Grossman A, Savage MO, Besser GM. Clinics in endocrinology and metabolism. 1986